Today: 7 February 2026
Subscribe
Browse Category

NYSE:BMY News 21 December 2025 - 5 February 2026

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares rose 1.7% to $58.58 by midday Thursday, bucking a broader market decline, after the company issued a 2026 outlook projecting up to $47.5 billion in revenue. Quarterly revenue increased 1% to $12.5 billion, with growth portfolio sales up 16% and legacy drugs down 15%. The company expects Eliquis sales to rise despite U.S. price negotiations, but warned of a potential $2 billion drop in 2027 when European patents expire.
5 February 2026
··
Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft shares fell 1.1% to $454.52 in after-hours trading Tuesday, tracking a broad tech selloff as tariff concerns rattled markets. Bristol Myers Squibb announced a partnership to use Microsoft’s AI radiology tools for early lung cancer detection. Investors are awaiting Microsoft’s fiscal Q2 earnings on Jan. 28 for updates on cloud and AI growth. The S&P 500 closed down 2.04%, Nasdaq off 2.38%.
20 January 2026
···
Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia stock slides as Trump tariff threats hit AI stocks; Microsoft, Broadcom fall

Nvidia dropped 3.4% to $179.83, dragging AI stocks lower as U.S. markets fell on tariff threats from President Trump over Greenland. The Nasdaq lost 1.6% and S&P 500 slid 1.3% in early trading. Morgan Stanley downgraded IT hardware, citing weak demand and high costs. Microsoft, Broadcom, and Palantir also declined, while AMD rose 1.3%.
20 January 2026
············
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts

Bristol Myers Squibb shares jumped 4.2% to $56.72 after UBS upgraded the stock to “buy” and raised its price target to $65. UBS cited upcoming catalysts but noted ongoing patent-expiry pressure through 2028. Trading volume exceeded averages as the stock outperformed peers on a down market day. Investors await the company’s Jan. 12 J.P. Morgan conference appearance and Feb. 5 quarterly results.
8 January 2026
·
Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

NEW YORK, Jan 3, 2026, 17:25 ET — Market closed Bristol-Myers Squibb shares ended down 0.9% at $53.46 on Friday, after the company confirmed it will present at J.P. Morgan’s annual healthcare conference on Jan. 12. JPMorgan Chase The San Francisco conference is the sector’s first major investor gathering of the year, often setting the tone for how traders price pipelines, deal appetite and 2026 outlooks. JPMorgan Chase For Bristol-Myers, the timing is sensitive. Investors are balancing a just-passed dividend cutoff with a Feb. 5 earnings report and a Medicaid pricing change for Eliquis that took effect on Jan. 1.
3 January 2026
··
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on the company’s pivot from clinical-stage developer to commercial operator, with investors looking for hard signals on pricing and early demand. For drug developers, the first few weeks of launch execution can reset expectations quickly. Cytokinetics has said Myqorzo is expected
1 January 2026
····
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

NEW YORK, December 30, 2025, 23:30 ET — Market closed Bristol-Myers Squibb Co. shares closed up 0.18% at $54.21 on Tuesday, after trading between $53.92 and $54.35. The stock has ranged from $42.52 to $63.33 over the past 52 weeks. Bristol Myers Squibb Investors The modest gain came as Wall Street drifted lower in holiday-thinned trade. “The growth rates are going to converge between technology and everything else next year,” said Mark Hackett, chief market strategist at Nationwide, as investors repositioned after a tech-led run; the S&P 500 slipped 0.14% and the Nasdaq fell 0.23%. Reuters Why it matters now:
31 December 2025
··
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

NEW YORK, December 29, 2025, 14:15 ET — Regular session Bristol Myers Squibb shares fell on Monday, with the drugmaker lagging a slightly weaker U.S. stock market in holiday-thinned trading. The stock was down 0.7% at $54.27 in afternoon trade. The move matters now because the final week of the year often brings abrupt swings on light volume, even when company-specific headlines are scarce. Bristol Myers is also approaching two calendar catalysts that can influence positioning: its next dividend record date and its next earnings report. U.S. stocks eased from record highs at the start of a holiday-shortened week, and
29 December 2025
···
Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

Bristol Myers stock drifts near $55 as year-end trading thins and Fed minutes loom

NEW YORK, December 28, 2025, 23:31 ET — Market closed Bristol Myers Squibb shares ended Friday slightly lower at $54.64, as the U.S. market headed into the year’s final trading days with few fresh company-specific catalysts. Bristol Myers Squibb That matters now because thin year-end liquidity — lower trading volume around the holidays — can amplify day-to-day swings, even when headlines are scarce. Investors are also adjusting portfolios into 2026, a process that can trigger abrupt sector rotations. Reuters For Bristol Myers, a large-cap drugmaker often traded as a defensive holding, the near-term tape is being shaped more by rates
29 December 2025
·
Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 2:53 PM ET, Market closed Bristol Myers Squibb Company (NYSE: BMY) enters the final trading stretch of 2025 with investors balancing a defensive “big pharma” profile and above-market income appeal against policy headlines and the long-running question hanging over the name: how quickly can new launches and pipeline catalysts offset upcoming loss-of-exclusivity (LOE) pressure in key franchises? With U.S. equity markets closed for the weekend, BMY’s most recent official print is Friday’s regular-session close at $54.64, down 0.13% on the day. The stock traded between $54.38 and $55.04 with volume of 9.57 million shares, sitting
28 December 2025
·
Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus

NEW YORK, Dec. 27, 2025, 5:15 p.m. ET — Market closed Bristol-Myers Squibb Company (NYSE: BMY) heads into the final week of 2025 with U.S. markets shut for the weekend and investor attention shifting to what could matter most when trading resumes Monday: year-end positioning, the company’s next dividend timeline, the next earnings checkpoint, and a set of 2026 regulatory and pipeline milestones that could influence sentiment around the stock. Where BMY stock stands heading into the last trading days of 2025 BMY shares finished the most recent session (Friday) at about $54.65, essentially flat on the day, and later
27 December 2025
···
Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open

NEW YORK, Dec. 27, 2025, 3:10 p.m. ET — Market closed Bristol-Myers Squibb Company (NYSE: BMY) stock is heading into the weekend with U.S. equity markets closed, leaving investors to digest the latest batch of institutional ownership updates and re-check near-term catalysts that could matter when trading resumes Monday. The pharmaceutical giant finished the most recent regular session (Friday) essentially flat, while broader benchmarks also showed little movement—typical of late-December, liquidity-thinner trading. Bristol Myers Squibb Investors BMY stock price recap: where shares last traded BMS’ investor relations quote page shows BMY at $54.64 as of Dec. 26 at 4:00 p.m.
27 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb Company (NYSE: BMY) heads into Dec. 25, 2025 with its stock anchored in the mid-$50s — and with investors juggling two competing storylines: With U.S. markets effectively pausing for the holiday, the most recent available NYSE quote showed BMY around $54.71 (last trade timestamp recorded Dec. 24), after trading between roughly $54.20 and $54.75 intraday. Bristol Myers Squibb Investors Bristol-Myers Squibb stock price today: where BMY stands into Dec. 25, 2025 BMS’s own investor quote page showed BMY at $54.71 on Dec. 24 (delayed quote), with a prior close listed as $54.28 and a 52-week range of $42.52
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended the Christmas Eve session with a modest gain—and then stayed largely quiet in after-hours trading as U.S. markets wrapped an early close and investors looked ahead to the next full session on Friday, Dec. 26 (U.S. markets are closed on Christmas Day, Dec. 25). New York Stock Exchange Even with the calm tape, today’s coverage of BMY wasn’t short on strong opinions: several market commentators leaned into the “value + dividend” case, while others argued the stock is now closer to fair value after a year-end rebound and policy headlines around Eliquis pricing. chartmill.com
25 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 23, 2025: Key News, Analyst Forecasts, and What to Watch Before the Dec. 24 Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended Tuesday, December 23, 2025, slightly lower in regular trading, then steadied after the closing bell as investors digested a fresh legal headline tied to U.S. drug pricing—plus a growing list of end‑of‑year catalysts that could shape sentiment into 2026. BMY finished the session at $54.26, down $0.41 (-0.74%), and traded modestly higher in extended hours at about $54.36 (+0.20%) as of the evening update. MarketBeat After-hours snapshot: where BMY stands tonight Even with the post-close bounce, Tuesday’s tape looked like a classic pre-holiday setup: a narrow move, lighter conviction, and investors focusing more on
24 December 2025
·
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a key growth product category. At the same time, Bristol Myers is heading into 2026 with a higher dividend, a defined near-term calendar (including a February earnings date), and intensifying debates over whether the stock’s “value” profile is a bargain—or a reflection of policy risk and the post-patent “reset” that still hangs over Big Pharma. BMY stock price today (December 23,
23 December 2025
··
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb Company (NYSE: BMY) ended Monday’s regular session on a modestly stronger note, then held near flat in after-hours trading as investors continued to weigh a fast-evolving U.S. drug-pricing landscape, BMS’s Eliquis-focused policy commitments, and a fresh dividend hike headed into 2026. Below is what’s moving BMY after the bell on December 22, 2025, and the key items investors will be watching into Tuesday’s open (Dec. 23)—including the latest headlines, Wall Street forecasts, and the open questions that could drive the next leg up or down. BMY stock after the bell: where shares closed and how after-hours trading looks
23 December 2025
··
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
1 2

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop